Tandem vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Reached $1B valuation (2026). Automates specialty drug prior auth, access barriers, and copay assistance for providers. Targets $500B+ specialty drug access bottleneck.
About
Tandem is a specialty drug access automation platform that has reached a $1 billion valuation in 2026, providing AI-powered automation of the full specialty pharmaceutical access workflow for healthcare providers — prior authorization submissions, access barrier management, copay assistance enrollment, and patient assistance program identification. The platform targets the $500+ billion specialty drug market where access friction is the primary barrier preventing patients from receiving prescribed medications.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.